News
SAVA
1.315
+1.15%
0.015
Weekly Report: what happened at SAVA last week (0331-0404)?
Weekly Report · 14h ago
Is the Future Bleak for SAVA Stock Following Another Setback?
NASDAQ · 03/31 14:00
Weekly Report: what happened at SAVA last week (0324-0328)?
Weekly Report · 03/31 10:39
Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus
Seeking Alpha · 03/30 13:05
Trending stocks this week as Wall Street wobbles
Seeking Alpha · 03/29 18:11
Biotech Alert: Searches spiking for these stocks today
TipRanks · 03/28 15:30
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More
NASDAQ · 03/26 14:02
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
NASDAQ · 03/26 11:43
Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful
Barchart · 03/25 21:12
Cassava Sciences announces Phase 3 REFOCUS-ALZ did not meet primary endpoint
TipRanks · 03/25 18:41
Cassava Sciences down 12% after simufilam doesn’t hit Alzheimer’s trial endpoint
TipRanks · 03/25 18:29
Morning Movers: Mobileye jumps following Volkswagen ADAS partnership
TipRanks · 03/25 18:24
H.C. Wainwright reiterates Neutral, $2 target on Cassava after AD trial data
TipRanks · 03/25 18:13
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 03/25 17:05
Cassava Sciences Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
Dow Jones · 03/25 15:51
HC Wainwright & Co. Reiterates Neutral on Cassava Sciences, Maintains $2 Price Target
Benzinga · 03/25 15:40
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
Benzinga · 03/25 14:42
Cassava Sciences’ Alzheimer’s Drug Trials Fall Short, Neutral Rating Maintained Amid Uncertainties
TipRanks · 03/25 14:15
Cassava Sciences Stock Falls as Alzheimer Drug Misses Targets, To Be Discontinued
Dow Jones · 03/25 14:15
BUZZ-Cassava falls after failing in second late-stage trial
Reuters · 03/25 13:44
More
Webull provides a variety of real-time SAVA stock news. You can receive the latest news about Cassava Sciences through multiple platforms. This information may help you make smarter investment decisions.
About SAVA
More
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.